Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma
NCT04153565Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in malignant pleural mesothelioma (MPM), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicity, Adverse Events at 34 months and 1 more. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04153565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153565.